Silvant Capital Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $103M | Buy |
112,338
+5,963
| +6% | +$6.05M | 3.57% | 8 |
|
|
2025
Q4 | $114M | Sell |
106,375
-3,689
| -3% | -$3.53M | 3.86% | 6 |
|
|
2025
Q3 | $84M | Buy |
110,064
+15,796
| +17% | +$11.8M | 2.91% | 10 |
|
|
2025
Q2 | $73.5M | Buy |
94,268
+601
| +0.6% | +$467K | 2.78% | 11 |
|
|
2025
Q1 | $77.4M | Buy |
93,667
+374
| +0.4% | +$311K | 3.56% | 7 |
|
|
2024
Q4 | $72M | Sell |
93,293
-172
| -0.2% | -$142K | 2.99% | 9 |
|
|
2024
Q3 | $82.8M | Sell |
93,465
-107
| -0.1% | -$96.2K | 3.63% | 6 |
|
|
2024
Q2 | $84.7M | Sell |
93,572
-4,996
| -5% | -$4M | 3.76% | 5 |
|
|
2024
Q1 | $76.7M | Sell |
98,568
-7,006
| -7% | -$4.99M | 3.66% | 6 |
|
|
2023
Q4 | $61.5M | Sell |
105,574
-2,752
| -3% | -$1.61M | 3.31% | 6 |
|
|
2023
Q3 | $58.2M | Sell |
108,326
-18,918
| -15% | -$9.75M | 3.52% | 6 |
|
|
2023
Q2 | $59.7M | Buy |
127,244
+3,465
| +3% | +$1.45M | 3.36% | 5 |
|
|
2023
Q1 | $42.5M | Sell |
123,779
-2,082
| -2% | -$702K | 2.77% | 7 |
|
|
2022
Q4 | $46M | Sell |
125,861
-20,142
| -14% | -$7.14M | 3.26% | 7 |
|
|
2022
Q3 | $47.2M | Buy |
146,003
+124,363
| +575% | +$39.4M | 3.21% | 8 |
|
|
2022
Q2 | $7.02M | Buy |
21,640
+32
| +0.1% | +$9.61K | 1.7% | 11 |
|
|
2022
Q1 | $6.19M | Sell |
21,608
-255
| -1% | -$65.6K | 1.18% | 14 |
|
|
2021
Q4 | $6.04M | Sell |
21,863
-948
| -4% | -$240K | 1.03% | 19 |
|
|
2021
Q3 | $5.27M | Sell |
22,811
-4,198
| -16% | -$1.04M | 0.94% | 21 |
|
|
2021
Q2 | $6.2M | Sell |
27,009
-444
| -2% | -$89.2K | 0.98% | 17 |
|
|
2021
Q1 | $5.13M | Buy |
27,453
+7,049
| +35% | +$1.38M | 0.88% | 23 |
|
|
2020
Q4 | $3.44M | Buy |
20,404
+18,818
| +1,187% | +$2.81M | 0.59% | 39 |
|
|
2020
Q3 | $235K | Hold |
1,586
| – | – | 0.04% | 163 |
|
|
2020
Q2 | $260K | Hold |
1,586
| – | – | 0.05% | 153 |
|
|
2020
Q1 | $220K | Hold |
1,586
| – | – | 0.05% | 145 |
|
|
2019
Q4 | $208K | Hold |
1,586
| – | – | 0.04% | 179 |
|
|
2019
Q3 | $177K | Sell |
1,586
-349
| -18% | -$38.9K | 0.04% | 183 |
|
|
2019
Q2 | $214K | Hold |
1,935
| – | – | 0.04% | 181 |
|
|
2019
Q1 | $251K | Hold |
1,935
| – | – | 0.05% | 168 |
|
|
2018
Q4 | $224K | Hold |
1,935
| – | – | 0.04% | 165 |
|
|
2018
Q3 | $208K | Hold |
1,935
| – | – | 0.03% | 189 |
|
|
2018
Q2 | $165K | Hold |
1,935
| – | – | 0.02% | 209 |
|
|
2018
Q1 | $150K | Buy |
+1,935
| New | +$156K | 0.02% | 216 |
|
Other funds holding LLY
VCM
VPM
Silvant Capital Management's LLY Position: Q1 2026 in Review
Silvant Capital Management increased its Eli Lilly (LLY) stake by 5.6% in Q1 2026, buying an estimated $6.05M and bringing the position to 112,338 shares worth $103M. The position accounts for 3.57% of the portfolio, ranked #8.
Silvant Capital Management first reported a position in LLY in Q1 2018 and has held it in 33 quarters since. The position peaked at $114M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Silvant Capital Management held 112,338 shares of Eli Lilly worth $103M as of Q1 2026.
- Silvant Capital Management bought 5,963 Eli Lilly shares in Q1 2026, an estimated $6.05M.
- Eli Lilly made up 3.57% of Silvant Capital Management's portfolio in Q1 2026, its #8 holding.
- Silvant Capital Management first reported a position in Eli Lilly in Q1 2018 and has held it in 33 quarters since.
- Silvant Capital Management's Eli Lilly position peaked at $114M in Q4 2025.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Silvant Capital Management's 13F filing for Q1 2026, filed 14 May 2026.